Home Machinery & Equipment Industrial Equipment Anti-obesity Medication Market

Anti-obesity Medication Market Size, Share & Trends Analysis Report By Product (Approved, Off Label), By Mechanism of Action (Peripherally Acting Drugs, Centrally Acting Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: March 09, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR5874DR | Pages: 160
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti-obesity Medication Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Approved
      1. Bupropion-naltrexone (Contrave)
      2. Liraglutide (Orlistat)
      3. Orlistat
        1. Xenical
        2. Alli
      4. Phentermine-topiramate (Qsymia)
      5. Semaglutide (Wegovy)
      6. Setmelanotide (Imcivree)
      7. Tirzepatide (Zepbound)
    2. Off Label
      1. Semaglutide (Xenical Alli)
      2. Liraglutide (Semaglutide (Wegovy))
      3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
      4. Others
  2. Anti-obesity Medication Market, By Mechanism of Action 2022-2034 (USD MILLION/ Units)
    1. Peripherally Acting Drugs
    2. Centrally Acting Drugs
  3. Anti-obesity Medication Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Retail Pharmacies
    2. Hospital Pharmacies
    3. Others
  4. Regional Anti-obesity Medication Market
    1. North America
      1. North America Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. North America Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. North America Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. U.S. Anti-obesity Medication Market
        1. U.S. Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. U.S. Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. U.S. Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      5. Canada Anti-obesity Medication Market
        1. Canada Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Canada Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Canada Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
    2. Europe
      1. Europe Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. Europe Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. Europe Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. U.K. Anti-obesity Medication Market
        1. U.K. Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. U.K. Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. U.K. Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      5. Germany Anti-obesity Medication Market
        1. Germany Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Germany Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Germany Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      6. France Anti-obesity Medication Market
        1. France Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. France Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. France Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      7. Spain Anti-obesity Medication Market
        1. Spain Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Spain Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Spain Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      8. Italy Anti-obesity Medication Market
        1. Italy Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Italy Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Italy Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      9. Russia Anti-obesity Medication Market
        1. Russia Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Russia Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Russia Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      10. Nordic Anti-obesity Medication Market
        1. Nordic Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Nordic Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Nordic Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      11. Benelux Anti-obesity Medication Market
        1. Benelux Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Benelux Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Benelux Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      12. Rest of Europe Anti-obesity Medication Market
        1. Rest of Europe Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Rest of Europe Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Rest of Europe Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
    3. APAC
      1. APAC Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. APAC Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. APAC Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. China Anti-obesity Medication Market
        1. China Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. China Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. China Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      5. Korea Anti-obesity Medication Market
        1. Korea Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Korea Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Korea Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      6. Japan Anti-obesity Medication Market
        1. Japan Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Japan Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Japan Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      7. India Anti-obesity Medication Market
        1. India Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. India Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. India Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      8. Australia Anti-obesity Medication Market
        1. Australia Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Australia Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Australia Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      9. Singapore Anti-obesity Medication Market
        1. Singapore Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Singapore Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Singapore Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      10. Taiwan Anti-obesity Medication Market
        1. Taiwan Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Taiwan Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Taiwan Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      11. South East Asia Anti-obesity Medication Market
        1. South East Asia Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. South East Asia Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. South East Asia Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      12. Rest of Asia-Pacific Anti-obesity Medication Market
        1. Rest of Asia-Pacific Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Rest of Asia-Pacific Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Rest of Asia-Pacific Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
    4. Middle East and Africa
      1. Middle East and Africa Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. Middle East and Africa Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. Middle East and Africa Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. UAE Anti-obesity Medication Market
        1. UAE Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. UAE Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. UAE Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      5. Turkey Anti-obesity Medication Market
        1. Turkey Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Turkey Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Turkey Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      6. Saudi Arabia Anti-obesity Medication Market
        1. Saudi Arabia Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Saudi Arabia Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Saudi Arabia Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      7. South Africa Anti-obesity Medication Market
        1. South Africa Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. South Africa Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. South Africa Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      8. Egypt Anti-obesity Medication Market
        1. Egypt Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Egypt Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Egypt Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      9. Nigeria Anti-obesity Medication Market
        1. Nigeria Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Nigeria Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Nigeria Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      10. Rest of MEA Anti-obesity Medication Market
        1. Rest of MEA Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Rest of MEA Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Rest of MEA Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
    5. LATAM
      1. LATAM Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. LATAM Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. LATAM Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. Brazil Anti-obesity Medication Market
        1. Brazil Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Brazil Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Brazil Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      5. Mexico Anti-obesity Medication Market
        1. Mexico Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Mexico Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Mexico Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      6. Argentina Anti-obesity Medication Market
        1. Argentina Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Argentina Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Argentina Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      7. Chile Anti-obesity Medication Market
        1. Chile Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Chile Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Chile Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      8. Colombia Anti-obesity Medication Market
        1. Colombia Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Colombia Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Colombia Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
      9. Rest of LATAM Anti-obesity Medication Market
        1. Rest of LATAM Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
          1. Approved
            1. Bupropion-naltrexone (Contrave)
            2. Liraglutide (Orlistat)
            3. Orlistat
              1. Xenical
              2. Alli
            4. Phentermine-topiramate (Qsymia)
            5. Semaglutide (Wegovy)
            6. Setmelanotide (Imcivree)
            7. Tirzepatide (Zepbound)
          2. Off Label
            1. Semaglutide (Xenical Alli)
            2. Liraglutide (Semaglutide (Wegovy))
            3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
            4. Others
        2. Rest of LATAM Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
          1. Peripherally Acting Drugs
          2. Centrally Acting Drugs
        3. Rest of LATAM Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Retail Pharmacies
          2. Hospital Pharmacies
          3. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.